Recommendation of the President – Vabinxo (valsartan + indapamide)
On 17 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 146/2024 on the appraisal of the drug Vabinxo (valsartan + indapamide) for the indication: treatment of spontaneous hypertension, as substitution treatment in adult patients adequately controlled with valsartan and indapamide administered simultaneously at the same dose as in combination, but as separate tablets